Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for atrial fibrillation
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Risk of Thromboembolism Associated With AtrialFibrillation Following Noncardiac Surgery The long-term risk of thromboembolism in patients developing new-onset post-operative atrialfibrillation (POAF) following noncardiac surgery is unknown, and data on stroke prophylaxis in this setting are lacking.The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular (...) atrialfibrillation (NVAF).Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes, previous thromboembolism, ischemic heart disease, and year of diagnosis to patients with nonsurgical NVAF in a 1:4 ratio. Comparative long-term risk of thromboembolism was examined by multivariable Cox regression models.In patients undergoing noncardiac surgery, 6,048
Usefulness of the CHA2DS2-VASc Score to Predict the Risk of Sudden Cardiac Death and Ventricular Arrhythmias in Patients With AtrialFibrillation Sudden cardiac death (SCD), the most devastating manifestation of ventricular arrhythmias (VAs), is the leading cause of mortality in patients with atrialfibrillation (AF). We hypothesized that the CHA2DS2-VASc score, consisting of age and several clinical risk factors, could be used to estimate the individual risk of SCD/VAs for AF patients. From
Low-dose Magnesium Sulfate Versus High Dose in the Early Management of Rapid AtrialFibrillation: Randomized Controlled Double-blind Study (LOMAGHI Study) We aim to determine the benefit of two different doses magnesium sulfate (MgSO4 ) compared to placebo in rate control of rapid atrialfibrillation (AF) managed in the emergency department (ED).We undertook a randomized, controlled, double-blind clinical trial in three university hospital EDs between August 2009 and December 2014. Patients
Is the Risk of Bleeding Among Older Adults With AtrialFibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? TAKE-HOME MESSAGE Older adults have a lower risk of any severity of bleeding (includes both major and minor bleeding) when treated with aspirin or clopidogrel compared to warfarin. However, if minor bleeding is excluded, only the subgroup of patients aged 80 years or older demonstrate a lower risk the of major bleeding with antiplatelet agents. Is the Risk of Bleeding (...) Among Older Adults With AtrialFibrillation Lower With Antiplatelet Compared With Oral Anticoagulants? EBEM Commentators Cameron Gettel, MD Elizabeth M. Goldberg, MD, ScM Department of Emergency Medicine Alpert Medical School of Brown University Providence, RI Results Commentary Several systematic reviews have previously shown that the risk of bleeding with long-term treatment with aspirin was lower than with warfarin. 2,3 It is common clinical practice to use antiplatelet agents as alternatives
Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With AtrialFibrillation? (SRS Diagnosis) TAKE-HOME MESSAGE Multidetector computed tomography (CT) is a sensitive test to detect left atrial thrombus in patients with atrial ?brillation. Can Multidetector Computed Tomography Rule Out Left Atrial Thrombus in Patients With AtrialFibrillation? EBEM Commentators Christopher J. Solie, DO Nicholas M. Mohr, MD, MS Daniel P. Runde, MD Department of Emergency Medicine (...) cardioversion of atrial ?brillation? J Am Coll Cardiol. 1994;23:533-541. 6. Romero J, Husain SA, Kelesidis I, et al. Detection of left atrial appendage thrombus by cardiac computed tomography inpatients with atrialfibrillation: a meta-analysis. Circ Cardiovasc Imaging. 2013;6:185-194. 7. Manning WJ, Weintraub RM, Waksmonski CA, et al. Accuracy of transesophageal echocardiography for identifying left atrial thrombi. A prospective, intraoperative study. Ann Intern Med. 1995;123:817-822. 8. Hwang JJ, Chen JJ
Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE In partnership with Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update October 2018Comparative Effectiveness Review Number 214 Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville (...) at: www.effectivehealthcare.ahrq.gov. Search on the title of the report. Persons using assistive technology may not be able to fully access information in this report. For assistance contact email@example.com. Suggested citation: Sanders GD, Lowenstern A, Borre E, Chatterjee R, Goode A, Sharan L, Allen LaPointe NM, Raitz G, Shah B, Yapa R, Davis JK, Lallinger K, Schmidt R, Kosinski A, Al-Khatib S. Stroke Prevention in Patients With AtrialFibrillation: A Systematic Review Update. Comparative Effectiveness Review No. 214. (Prepared
Standardized Library of AtrialFibrillation Outcome Measures Research White Paper Standardized Library of AtrialFibrillation Outcome Measures Research White Paper Standardized Library of AtrialFibrillation Outcome Measures Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC With partner: OM1, AcademyHealth (...) access information in this report. For assistance contact firstname.lastname@example.org. Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of AtrialFibrillation Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 18(19)-EHC026-EF. Rockville, MD: Agency for Healthcare Research and Quality; November 2018. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org
Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of AtrialFibrillation 2018 CCS Focused Update of the Guidelines for the Management of AtrialFibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Laurent Macle Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier Johnson & Johnson, Servier Atul Verma Bayer, Johnson & Johnson, Medtronic Johnson & Johnson Jason Andrade Bayer, BMS Pfizer, Medtronic, Servier (...) process. Below is a list of all disclosures for the AF panel, regardless of relevance to the 2018 AF Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca. Page 1 2018 CCS Focused Update of the Guidelines for the Management of AtrialFibrillation Consulting Fees/ Honoraria Clinical Trials Other Financial Benefit Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content
Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrialfibrillation? Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrialfibrillation? - CanadiEM Blood & Clots Series: How do you choose an anticoagulant for stroke prevention in atrialfibrillation? In , by Kerstin de Wit October 23, 2018 All the content from the Blood & Clots series can be found . CanMEDS Roles addressed : Expert, health advocate, communicator Case (...) Description A 52 year old lady attends the emergency department with a several week history of palpitations. She is found to have atrialfibrillation. You have started a beta blocker and she is in a stable condition for discharge. You evaluate the need for stroke prevention and discuss the options with her. Main Text A 52 year old lady attends the emergency department with previously unrecognized atrialfibrillation. She has had intermittent palpitations for a month or so and her first ECG showed atrial
Chronic atrialfibrillation Chronic atrialfibrillation - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Chronic atrialfibrillation Last reviewed: February 2019 Last updated: October 2018 Summary Chaotic and irregular atrial arrhythmia, the prevalence of which increases progressively with age. Patients frequently have co-existing cardiac or non-cardiac conditions, such as hypertension, coronary artery disease (...) , pacemakers, and ablation of the atrioventricular node need to be weighed based on multiple clinical factors to optimise patient outcome. Definition Atrialfibrillation (AF) is a supraventricular tachyarrhythmia. It is characterised by uncoordinated atrial activity on the surface ECG, with fibrillatory waves of varying shapes, amplitudes, and timing associated with an irregularly irregular ventricular response when atrioventricular (AV) conduction is intact. [Figure caption and citation for the preceding
Newer technologies for detection of atrialfibrillation. Atrialfibrillation is a common arrhythmia that is associated with increased risk of stroke, which can be reduced with appropriate anticoagulation treatment. However, it remains underdiagnosed in contemporary clinical practice using conventional detection methods, resulting in missed opportunities to implement appropriate treatment. Newer technologies developed in recent years can potentially enhance the detection of atrialfibrillation (...) and overcome certain limitations of the conventional methods. However, uncertainties remain about their use and the significance of atrialfibrillation detected by some of these newer technologies. This review examines the evidence supporting the use of some of these technologies and evaluates their applications in certain clinical scenarios.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights
Using the MB-LATER score for predicting arrhythmia outcome after catheter ablation for atrialfibrillation: The Guangzhou atrialfibrillation project Several clinical scoring systems have been derived to predict the arrhythmia outcome of catheter ablation (CA) for atrialfibrillation (AF) but which is better is not clear. Simple clinical risk scores (that any clinician can use in the everyday clinic) can help assess the likelihood of recurrence of AF following CA and the simple MB-LATER score
A randomized controlled trial of atrioventricular junction ablation and cardiac resynchronization therapy in patients with permanent atrialfibrillation and narrow QRS We tested the hypothesis that atrioventricular (AV) junction ablation in conjunction biventricular pacing [cardiac resynchronization (CRT)] pacing is superior to pharmacological rate-control therapy in reducing heart failure (HF) and hospitalization in patients with permanent atrialfibrillation (AF) and narrow QRS.We randomly
Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for AtrialFibrillation. Stroke rates in patients with nonvalvular atrialfibrillation (AF) who are not receiving anticoagulant therapy vary widely across published studies; the resulting effect on the net clinical benefit of anticoagulation in AF is unknown.To determine the effect of variation in published AF stroke rates on the net clinical benefit of anticoagulation.Markov model decision analysis (...) and Risk Factors In AtrialFibrillation) study and greatest using those from the Danish National Patient Registry (6290 QALYs [95% CI, ±2.3%] vs. 24 110 QALYs [CI, ±1.9%]; P < 0.001). The optimal CHA2DS2-VASc score threshold for anticoagulation was 3 or more using stroke rates from ATRIA, 2 or more using those from the Swedish AF cohort study, 1 or more using those from the SPORTIF (Stroke Prevention using ORal Thrombin Inhibitor in atrialFibrillation) study, and 0 or more using those from the Danish
Association of metabolic syndrome with non-thromboembolic adverse cardiac outcomes in patients with atrialfibrillation Evidence suggests an excess risk of non-thromboembolic major adverse cardiac events (MACE) associated with atrialfibrillation (AF), particularly in individuals free of overt coronary artery disease (CAD). Metabolic syndrome (MetS) increases cardiovascular risk in the general population, but less is known how it influences outcomes in AF patients. We aimed to assess whether
Screening for AtrialFibrillation With Electrocardiography: US Preventive Services Task Force Recommendation Statement. Atrialfibrillation is the most common type of cardiac arrhythmia (irregular heartbeat), and its prevalence increases with age, affecting about 3% of men and 2% of women aged 65 to 69 years and about 10% of adults 85 years and older. Atrialfibrillation is a major risk factor for ischemic stroke, increasing risk of stroke by as much as 5-fold. Approximately 20% of patients who (...) have a stroke associated with atrialfibrillation are first diagnosed with atrialfibrillation at the time of stroke or shortly thereafter.To issue a new US Preventive Services Task Force (USPSTF) recommendation on screening for atrialfibrillation with electrocardiography (ECG).The USPSTF reviewed the evidence on the benefits and harms of screening for atrialfibrillation with ECG in adults 65 years and older, the effectiveness of screening with ECG for detecting previously undiagnosed atrial
Clinical outcomes of patients with diabetes and atrialfibrillation treated with apixaban: results from the ARISTOTLE trial. We compared clinical outcomes in patients with AF with and without diabetes in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in AtrialFibrillation trial.The main efficacy endpoints were SSE and mortality; safety endpoints were major and major/clinically relevant non-major bleeding. A total of 4547/18 201 (24.9%) patients had diabetes who were
Atrialfibrillation Top results for atrialfibrillation - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look (...) like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for atrialfibrillation The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials
Should Patients Undergo AtrialFibrillation Screening for Primary Stroke Prevention? Should Patients Undergo AtrialFibrillation Screening for Primary Stroke Prevention? – Clinical Correlations Search Should Patients Undergo AtrialFibrillation Screening for Primary Stroke Prevention? July 26, 2018 7 min read By Dixon Yang, MD Peer Reviewed Abstract Atrialfibrillation (AF) is a common arrhythmia, especially in the elderly, and is often asymptomatic. However, absence of symptoms does not confer (...) be interpreted with caution. While a significant portion of patients with screen-detected AF may qualify for anticoagulation, it is unclear which patients would benefit with improved vascular outcomes. Introduction Atrialfibrillation (AF) is a sustained arrhythmia commonly encountered in clinical practice, especially in those over age 65. [1,2]. However, absence of symptoms does not confer a better prognosis and is . Up to 5% of patients with AF present with ischemic stroke as their first manifestation
Usefulness of the Addition of Renal Function to the CHA2DS2-VASc Score as a Predictor of Thromboembolism and Mortality in Patients Without AtrialFibrillation Research is conflicting whether kidney function should be incorporated in thromboembolism risk prediction. Our published data showed that the CHA2DS2-VASc score predicts thromboembolism and mortality in those without atrialfibrillation. We used the Rochester Epidemiology Project medical records system to retrospectively evaluate whether (...) adding renal impairment (1 point) to the CHA2DS2-VASc score (-R) enhances the score's prediction of mortality, thromboembolism, and atrialfibrillation in patients without atrialfibrillation. We identified patients that had an implantable cardiac monitoring device placed from January 1, 2004 to December 31, 2013, which was defined as the start date. Follow-up was through March 7, 2016. An implantable device was required to discern the absence of atrialfibrillation. Renal impairment was defined